Factor H-binding protein, a unique meningococcal vaccine antigen.
GNA1870, also named factor H-binding protein (fHbp) or rLP-2086, is a genome-derived antigen and one of the components of a rationally designed vaccine against Neisseria meningitidis serogroup B, which has entered phase III clinical trials. It has been classified into three main non-cross-protective variant groups. GNA1870 has also been termed fHbp because of its ability to bind factor H, a key regulatory component of the alternative complement pathway. fHbp is important for survival in human blood, human sera, and in presence of antimicrobial peptides, independently of its expression level. All these properties make fHbp a unique vaccine antigen.
Pizza
Mariagrazia
M
Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy. mariagrazia.pizza@novartis.com
Donnelly
John
J
Rappuoli
Rino
R
D000911:Antibodies, Monoclonal / Q000276:immunology; D000942:Antigens, Bacterial / Q000737:chemistry / Q000276:immunology* / Q000502:physiology; D001426:Bacterial Proteins / Q000737:chemistry / Q000276:immunology* / Q000502:physiology; D000939:Epitopes; D006801:Humans; D022401:Meningococcal Vaccines / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D000939:Epitopes; D022401:Meningococcal Vaccines; C484699:factor H-binding protein, Neisseria meningitidis